| CONSENSUS | Cooperative North Scandinavian Enalapril Survival Study |
|---|---|
| SMN | second malignant neoplasm; stathmin |
| Tabs | tablets |
| E | Enalapril |
|---|---|
| EN | Enalapril |
| ENA | Enalapril |
| SMN | Second Malignant Neoplasm |
| SMN | Survival Motor Neuron |
| enalapril | <chemical> Orally active inhibitor of kininase II. It controls essential and renal hypertension, improves glomerular filtration rate and effective renal blood flow, and decreases renal vascular resistance without producing adverse effects on salt and water excretion or body fluid composition. Pharmacological action: angiotensin-converting enzyme inhibitors, antihypertensive agents. Chemical name: L-Proline, 1-(N-(1-(ethoxycarbonyl)-3-phenylpropyl)-L-alanyl)-, (S)- (12 Dec 1998) |
|---|---|
| enalapril maleate | L-Proline, 1-[N-[1-(ethoxycarbonyl)-3-phenylpropyl]-l-alanyl]-,(S)-, (Z)-2-butenedioate (1:1);a prodrug for enalaprilat, an angiotensin-converting enzyme inhibitor used as an anti-hypertensive agent. (05 Mar 2000) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|---|---|---|---|
|
삼남에날라프릴정10mg - 새창
|
삼남제약 |
A11850501 | Enalapril maleate | 전문의약품 | 급여 |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|